222 related articles for article (PubMed ID: 21937449)
1. CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope.
Mak AB; Blakely KM; Williams RA; Penttilä PA; Shukalyuk AI; Osman KT; Kasimer D; Ketela T; Moffat J
J Biol Chem; 2011 Nov; 286(47):41046-56. PubMed ID: 21937449
[TBL] [Abstract][Full Text] [Related]
2. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.
Kemper K; Sprick MR; de Bree M; Scopelliti A; Vermeulen L; Hoek M; Zeilstra J; Pals ST; Mehmet H; Stassi G; Medema JP
Cancer Res; 2010 Jan; 70(2):719-29. PubMed ID: 20068153
[TBL] [Abstract][Full Text] [Related]
3. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
[TBL] [Abstract][Full Text] [Related]
4. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
Bidlingmaier S; Zhu X; Liu B
J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
[TBL] [Abstract][Full Text] [Related]
5. Alpha2,3-Sialylation regulates the stability of stem cell marker CD133.
Zhou F; Cui C; Ge Y; Chen H; Li Q; Yang Z; Wu G; Sun S; Chen K; Gu J; Jiang J; Wei Y
J Biochem; 2010 Sep; 148(3):273-80. PubMed ID: 20551139
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma cells negative for the anti-CD133 antibody AC133 express a truncated variant of the CD133 protein.
Osmond TL; Broadley KW; McConnell MJ
Int J Mol Med; 2010 Jun; 25(6):883-8. PubMed ID: 20428792
[TBL] [Abstract][Full Text] [Related]
7. Insight into the complex regulation of CD133 in glioma.
Campos B; Herold-Mende CC
Int J Cancer; 2011 Feb; 128(3):501-10. PubMed ID: 20853315
[TBL] [Abstract][Full Text] [Related]
8. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer.
Florek M; Haase M; Marzesco AM; Freund D; Ehninger G; Huttner WB; Corbeil D
Cell Tissue Res; 2005 Jan; 319(1):15-26. PubMed ID: 15558321
[TBL] [Abstract][Full Text] [Related]
9. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells.
Lehnus KS; Donovan LK; Huang X; Zhao N; Warr TJ; Pilkington GJ; An Q
Int J Oncol; 2013 Mar; 42(3):1011-7. PubMed ID: 23340741
[TBL] [Abstract][Full Text] [Related]
10. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection.
Sgambato A; Puglisi MA; Errico F; Rafanelli F; Boninsegna A; Rettino A; Genovese G; Coco C; Gasbarrini A; Cittadini A
J Cell Physiol; 2010 Jul; 224(1):234-41. PubMed ID: 20333645
[TBL] [Abstract][Full Text] [Related]
11. N-glycan structures and associated gene expression reflect the characteristic N-glycosylation pattern of human hematopoietic stem and progenitor cells.
Hemmoranta H; Satomaa T; Blomqvist M; Heiskanen A; Aitio O; Saarinen J; Natunen J; Partanen J; Laine J; Jaatinen T
Exp Hematol; 2007 Aug; 35(8):1279-92. PubMed ID: 17662891
[TBL] [Abstract][Full Text] [Related]
12. Two novel monoclonal antibodies against human CD133-2: distinct epitopes and agonist activity to enhance growth of CD133 expression cells in vitro.
Wang J; Li F; Zhang G; Chen Y; Hu Y; Chen X; Lu B; Zhang X
Hybridoma (Larchmt); 2010 Jun; 29(3):241-9. PubMed ID: 20569000
[TBL] [Abstract][Full Text] [Related]
13. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping.
Wuchter C; Ratei R; Spahn G; Schoch C; Harbott J; Schnittger S; Haferlach T; Creutzig U; Sperling C; Karawajew L; Ludwig WD
Haematologica; 2001 Feb; 86(2):154-61. PubMed ID: 11224484
[TBL] [Abstract][Full Text] [Related]
14. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
[TBL] [Abstract][Full Text] [Related]
15. RNA aptamers targeting cancer stem cell marker CD133.
Shigdar S; Qiao L; Zhou SF; Xiang D; Wang T; Li Y; Lim LY; Kong L; Li L; Duan W
Cancer Lett; 2013 Mar; 330(1):84-95. PubMed ID: 23196060
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines.
Jaksch M; Múnera J; Bajpai R; Terskikh A; Oshima RG
Cancer Res; 2008 Oct; 68(19):7882-6. PubMed ID: 18829544
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel monoclonal antibody recognizing CD133.
Swaminathan SK; Olin MR; Forster CL; Cruz KS; Panyam J; Ohlfest JR
J Immunol Methods; 2010 Sep; 361(1-2):110-5. PubMed ID: 20674577
[TBL] [Abstract][Full Text] [Related]
18. Stem cell marker prominin-1/AC133 is expressed in duct cells of the adult human pancreas.
Lardon J; Corbeil D; Huttner WB; Ling Z; Bouwens L
Pancreas; 2008 Jan; 36(1):e1-6. PubMed ID: 18192867
[TBL] [Abstract][Full Text] [Related]
19. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.
Lang J; Lan X; Liu Y; Jin X; Wu T; Sun X; Wen Q; An R
Nucl Med Biol; 2015 May; 42(5):505-512. PubMed ID: 25669587
[TBL] [Abstract][Full Text] [Related]
20. Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth.
Liu Y; Ren S; Xie L; Cui C; Xing Y; Liu C; Cao B; Yang F; Li Y; Chen X; Wei Y; Lu H; Jiang J
Oncotarget; 2015 Aug; 6(24):20650-60. PubMed ID: 26029999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
